humanized

Omalizumab is a recombinant humanized monoclonal antibody against human immunoglobulin E IgE)

Recombinant Humanized Type III Collagen 30-40kDa is an innovative biomaterial with anticancer properties. It can activate discoidin domain receptor 1 (DDR1), thereby inhibiting cancer cell autophagy, proliferation, and migration, while inducing apoptosis.

Anti-CD3 Antibody (OKT-3, humanized) is a humanized OKT3-derived anti-CD3 antibody developed based on Muromonab-CD3 (OKT3, T76719), with reduced immunogenicity relative to the original murine antibody. Anti-CD3 Antibody (OKT-3, humanized) is applicable to immunological research involving T-cell receptor signaling, lymphocyte activation, and immune modulation in translational and preclinical experimental systems.

Anti-Human CD47 Antibody (B6H12, humanized) is an antibody that specifically targets human CD47; it blocks the interaction between CD47 and SIRPα and enhances the phagocytosis of tumour cells by macrophages in vitro. It can be used in research into macrophage-mediated phagocytosis, immune evasion and tumour immunology.

Humanized anti-tac (HAT) binding peptide is a peptide that specifically binds to the Fc region of HAT. HAT is a humanized monoclonal antibody targeting the low-affinity p55 subunit of the interleukin IL-2 receptor. The peptide can be utilized in the development of affinity chromatography media for the purification of specific monoclonal antibodies.

Recombinant Humanized Type III Collagen 28.6kDa is a synthesized form of humanized Type III collagen with a molecular weight of 28.6kDa. Known as rhCOLIII, it serves multiple biological functions, such as enhancing skin extracellular matrix regeneration and improving the cellular microenvironment. It inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen is involved in cell adhesion, migration, proliferation, and differentiation through interactions with integrins.

Recombinant humanized type III collagen (MW 55900) is a recombinant humanized collagen protein, with a molecular weight of 55900 Da, that offers diverse biological functions, such as enhancing skin extracellular matrix regeneration and improving the cellular microenvironment. This compound inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen plays a role in cell adhesion, migration, proliferation, and differentiation through interactions with integrins.

Recombinant Humanized Type XVII Collagen is a transmembrane protein that forms hemidesmosomes. It facilitates interactions between stem cells, surrounding cells, and the extracellular matrix, thereby regulating skin homeostasis, aging, and wound healing. Additionally, Recombinant Humanized Type XVII Collagen has distinct cell adhesion sites and signal transduction capabilities, which can modulate cell migration, proliferation, and differentiation.

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

Ocaratuzumab (AME-133v) is an Fc-engineered antibody and humanized monoclonal antibody targeting CD20 (Kd≈100 pM), exhibiting antibody-dependent cellular cytotoxicity (ADCC) in chronic lymphocytic leukemia.

Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting GD2 with antitumor activity, used to study neuroblastoma, osteosarcoma, and other GD2-positive cancers.

Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5

Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR with potential anticancer activity that blocks EGFR activation and downstream signaling for the study of non-small cell lung cancer.

Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

Mepolizumab (SB 240563) is a humanized monoclonal antibody that neutralizes IL-5, and can be utilized in research on severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.

Sacituzumab (hRS7) is an antibody inhibitor and a humanized monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2), serving as a component of the antibody-drug conjugate sacituzumab govitecan, used for research and treatment of TROP2-high-expressing tumors such as triple-negative breast cancer.

Ponsegromab (PF 06946860) is a selective and potent humanized anti-GDF15 antibody inhibitor with IC₅₀ values of 0.123 nM, 0.053 nM, and 0.102 nM for human, rhesus macaque, and mouse targets, respectively. Ponsegromab exhibits anti-cachexia activity by binding to GDF15 to prevent its interaction with GFRAL, thereby disrupting GDF15/GFRAL-mediated signaling. Ponsegromab possesses potential anticancer activity and may be used to treat cancer patients with cancer anorexia-cachexia syndrome. Ponsegromab acts as a chemopreparative agent, increasing intracellular reactive oxygen species levels and reducing glutathione levels.

Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.

Human IgG1 kappa, Isotype Control is a humanized IgG-like monoclonal antibody and an isotype control antibody for human IgG1κ.

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

Avelumab is a humanized anti-PD-L1 monoclonal antibody that binds to PD-L1 with high specificity (Kd = 0.1 nM) and exhibits potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab exerts a dual mechanism of action, combining direct antitumor activity with ADCC. Avelumab is used in research on cancers such as Merkel cell carcinoma.

Bevacizumab, a humanized monoclonal antibody, specifically and with high affinity binds to all isoforms of VEGF-A.